Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company said all doses achieved statistically significant reductions in body weight compared with placebo at 72 weeks
Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
The standout story remains Wegovy, particularly its new oral formulation
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
Lifts full-year outlook as obesity drug boom accelerates
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Subscribe To Our Newsletter & Stay Updated
